CJC-1295 vs AOD-9604
A comprehensive, data-driven comparison of CJC-1295 (Modified GRF 1-29) and AOD-9604 (Advanced Obesity Drug). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | CJC-1295 Modified GRF 1-29, DAC:GRF | AOD-9604 Advanced Obesity Drug, Tyr-hGH Fragment 176-191 |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Phase 2 (failed; reclassification pending) |
| Category | Growth Hormone | Weight Loss |
| Primary Use | Growth hormone optimization and anti-aging | Fat loss and metabolism enhancement |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $30 - $60/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1-2mg twice weekly (with DAC) | 300mcg daily |
| Frequency | Twice weekly | Daily |
| Mechanism | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone | Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1 |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Low |
| Clinical Trial Phase | N/A | Phase 2 |
Key Differences
- 1AOD-9604 is generally more affordable ($30 - $60/mo) compared to CJC-1295 ($35 - $70/mo).
- 2CJC-1295 is dosed twice weekly, while AOD-9604 is daily.
- 3AOD-9604 has low-quality evidence, while CJC-1295 has emerging-quality evidence.
- 4They belong to different categories: CJC-1295 (Growth Hormone) vs AOD-9604 (Weight Loss).
Which Is Better For...
AOD-9604
More budget-friendly option with lower monthly costs
CJC-1295
More convenient dosing schedule (twice weekly)
AOD-9604
Fewer commonly reported side effects
AOD-9604
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. They differ in FDA approval status, efficacy data, and cost.
CJC-1295 typically costs $35 - $70/mo, while AOD-9604 costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideAOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sug...
View Full AOD-9604 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between CJC-1295 and AOD-9604 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.